West Roxbury, MA, United States of America

Adriana Donovan

USPTO Granted Patents = 11 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 40(Granted Patents)

Location History:

Boston, MA (US) (2007)
West Roxbury, MA (US) (2009 - 2024)

Company Filing History:

Children's Medical Center Corporation

patents

1 out of 2

Children's Medical Center Coporation

patents

Years Active: 2007-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297262 - RGMC-selective inhibitors and use thereof (2025-05-13),

2. 12006359 - Methods for altering body composition by administering anti-pro/latent myostatin antibodies (2024-06-11),

3. 11439704 - Methods for using anti-myostatin antibodies (2022-09-13),

4. 11155611 - Compositions and methods for making and using anti-myostatin antibodies (2021-10-26),

5. 10946036 - Use of myostatin inhibitors and combination therapies (2021-03-16),

6. 10882904 - Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies (2021-01-05),

7. 10751413 - Anti-pro/latent-Myostatin antibodies and uses thereof (2020-08-25),

8. 10287345 - Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies (2019-05-14),

9. 8133974 - Ferroportin1 nucleic acids, proteins, antibodies and methods (2012-03-13),

10. 7521055 - Ferroportin1 antibodies and methods (2009-04-21),

11. 7166448 - Ferroportin1 nucleic acids and proteins (2007-01-23),

Title: Adriana Donovan: Innovator in Therapeutic Antibodies

Introduction

Adriana Donovan is a prominent inventor based in West Roxbury, MA (US). She has made significant contributions to the field of therapeutic antibodies, holding a total of 11 patents. Her work focuses on innovative solutions for various medical disorders, showcasing her dedication to advancing healthcare.

Latest Patents

Among her latest patents, Donovan has developed RGMC-selective inhibitors and methods for altering body composition through the use of anti-pro/latent myostatin antibodies. The RGMC-selective inhibitors target repulsive guidance molecule C (RGMc) and provide therapeutic applications for treating disorders such as anemia. Additionally, her work on antibodies that specifically bind pro-myostatin and/or latent myostatin presents new methods and uses for improving body composition.

Career Highlights

Throughout her career, Donovan has worked with notable organizations, including Scholar Rock, Inc. and Children's Medical Center Corporation. Her experience in these companies has allowed her to collaborate on groundbreaking research and development projects that aim to improve patient outcomes.

Collaborations

Adriana has collaborated with talented individuals such as Michelle Marie Straub and Stefan Wawersik. These partnerships have contributed to her success and the advancement of her innovative projects.

Conclusion

Adriana Donovan's contributions to the field of therapeutic antibodies and her impressive portfolio of patents highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.